12:00 AM
Jun 11, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Subcutaneous Orencia abatacept: Phase IIIb data

The double-blind, international Phase IIIb AMPLE trial in 646 patients with active moderate to severe RA who had an inadequate response to methotrexate showed that once-weekly subcutaneous 125 mg Orencia plus methotrexate met the primary endpoint of non-inferiority to 40 mg Humira adalimumab every other week plus methotrexate in the proportion of patients achieving an ACR20 response at 1 year (64.8% vs. 63.4%). At week 4, ACR20 response...

Read the full 340 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >